1 All‐cause mortality‐at 31 to 100 days |
2 |
95 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.25 [0.02, 2.69] |
2 Mortality due to chemotherapy |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
3 Number of participants with any bleeding |
2 |
149 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.73, 1.18] |
4 Number of participants with clinically significant bleeding |
2 |
149 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.75, 1.43] |
5 Severe or life‐threatening bleeding events |
2 |
149 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.57 [0.39, 6.30] |
6 Number of participants with serious infection episodes |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
7 Number of participants with VOD |
1 |
|
Peto Odds Ratio (Peto, Fixed, 95% CI) |
Totals not selected |
8 Number of participants with RBC transfusion from study entry |
3 |
155 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.90, 1.05] |
9 Number of participants with RBC Transfusion after reaching Hb >80 g/L for restrictive & Hb > 120 g/L for liberal |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
10 Mean number of RBC (units) transfusions per participant during the entire study period |
2 |
95 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.58 [‐5.66, ‐1.49] |
11 Number of participants with PLT transfusions from the study entry |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |